{
    "id": 9835,
    "fullName": "PTPN11 E76K",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "PTPN11 E76K lies within the SH2 domain 1 of the Ptpn11 protein (UniProt.org). E76K confers a gain of function to the Ptpn11 protein as demonstrated by increased protein tyrosine phosphatase activity, Erk1/2 phosphorylation, and migration, invasion, and transformation of cultured cells (PMID: 17942397, PMID: 29568093, PMID: 31807022), and induces increased chromosome instability (PMID: 26755576), promotes tumor formation in mouse models (PMID: 31807022), and is associated with resistance to a Shp2 inhibitor (PMID: 29568093).",
            "references": [
                {
                    "id": 3365,
                    "pubMedId": 17942397,
                    "title": "Shp2E76K mutant confers cytokine-independent survival of TF-1 myeloid cells by up-regulating Bcl-XL.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17942397"
                },
                {
                    "id": 17808,
                    "pubMedId": 31807022,
                    "title": "Gain-Of-Function E76K-Mutant SHP2 Promotes Cell Proliferation, Metastasis, And Tumor Growth In Glioblastoma Through Activation Of The ERK/CREB Pathway.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31807022"
                },
                {
                    "id": 15435,
                    "pubMedId": 26755576,
                    "title": "Gain-of-function mutations of Ptpn11 (Shp2) cause aberrant mitosis and increase susceptibility to DNA damage-induced malignancies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26755576"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 15436,
                    "pubMedId": 29568093,
                    "title": "Selective inhibition of leukemia-associated SHP2E69K mutant by the allosteric SHP2 inhibitor SHP099.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29568093"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 5781,
        "geneSymbol": "PTPN11",
        "terms": [
            "PTPN11",
            "BPTP3",
            "CFC",
            "JMML",
            "METCDS",
            "NS1",
            "PTP-1D",
            "PTP2C",
            "SH-PTP2",
            "SH-PTP3",
            "SHP2"
        ]
    },
    "variant": "E76K",
    "createDate": "07/30/2015",
    "updateDate": "02/19/2020",
    "referenceTranscriptCoordinates": {
        "id": 96193,
        "transcript": "NM_002834",
        "gDna": "chr12:g.112450406G>A",
        "cDna": "c.226G>A",
        "protein": "p.E76K",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 3984,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, hematopoietic progenitor cells expressing PTPN11 E76K were sensitive to II-B08, resulting in decreased cell proliferation (PMID: 20170098).",
            "molecularProfile": {
                "id": 9830,
                "profileName": "PTPN11 E76K"
            },
            "therapy": {
                "id": 2963,
                "therapyName": "II-B08",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3348,
                    "pubMedId": 20170098,
                    "title": "Salicylic acid based small molecule inhibitor for the oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20170098"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3983,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, myeloid cells harboring PTPN11 E76K were sensitive to cryptotanshinone in culture, resulting in decreased cell growth (PMID: 23957426).",
            "molecularProfile": {
                "id": 9830,
                "profileName": "PTPN11 E76K"
            },
            "therapy": {
                "id": 3415,
                "therapyName": "Cryptotanshinone",
                "synonyms": null
            },
            "indication": {
                "id": 50458,
                "name": "juvenile myelomonocytic leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4300,
                    "pubMedId": 23957426,
                    "title": "Identification of cryptotanshinone as an inhibitor of oncogenic protein tyrosine phosphatase SHP2 (PTPN11).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23957426"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2641,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PD98059 induced apoptotic activity of leukemia cells expressing PTPN11 E76K in culture (PMID: 17942397).",
            "molecularProfile": {
                "id": 9830,
                "profileName": "PTPN11 E76K"
            },
            "therapy": {
                "id": 2617,
                "therapyName": "PD98059",
                "synonyms": null
            },
            "indication": {
                "id": 1240,
                "name": "leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3365,
                    "pubMedId": 17942397,
                    "title": "Shp2E76K mutant confers cytokine-independent survival of TF-1 myeloid cells by up-regulating Bcl-XL.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17942397"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2640,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, U0126 induced apoptotic activity of leukemia cells expressing PTPN11 E76K in culture (PMID: 17942397).",
            "molecularProfile": {
                "id": 9830,
                "profileName": "PTPN11 E76K"
            },
            "therapy": {
                "id": 2427,
                "therapyName": "U0126",
                "synonyms": null
            },
            "indication": {
                "id": 1240,
                "name": "leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3365,
                    "pubMedId": 17942397,
                    "title": "Shp2E76K mutant confers cytokine-independent survival of TF-1 myeloid cells by up-regulating Bcl-XL.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17942397"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17451,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SHP099 had no effect on Erk1/2 phosphorylation, Bcl-xl expression, Parp cleavage, and growth of myeloid cells expressing PTPN11 E76K in culture (PMID: 29568093).",
            "molecularProfile": {
                "id": 9830,
                "profileName": "PTPN11 E76K"
            },
            "therapy": {
                "id": 4504,
                "therapyName": "SHP099",
                "synonyms": null
            },
            "indication": {
                "id": 8692,
                "name": "myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15436,
                    "pubMedId": 29568093,
                    "title": "Selective inhibition of leukemia-associated SHP2E69K mutant by the allosteric SHP2 inhibitor SHP099.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29568093"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15987,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of PTPN11 E76K in colorectal cancer cells harboring BRAF G596R abolished their sensitivity to RMC-4550-induced inhibition of Erk phosphorylation and proliferation in culture (PMID: 30104724).",
            "molecularProfile": {
                "id": 31353,
                "profileName": "BRAF G596R PTPN11 E76K"
            },
            "therapy": {
                "id": 7839,
                "therapyName": "RMC-4550",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 14089,
                    "pubMedId": 30104724,
                    "title": "RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30104724"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15990,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of PTPN11 E76K in lung cancer cells harboring NF1 N184fs abolished their sensitivity to RMC-4550-induced inhibition of Erk phosphorylation and proliferation in culture (PMID: 30104724).",
            "molecularProfile": {
                "id": 31356,
                "profileName": "NF1 N184fs PTPN11 E76K"
            },
            "therapy": {
                "id": 7839,
                "therapyName": "RMC-4550",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 14089,
                    "pubMedId": 30104724,
                    "title": "RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30104724"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 9830,
            "profileName": "PTPN11 E76K",
            "profileTreatmentApproaches": [
                {
                    "id": 7350,
                    "name": "SHP2 Inhibitor",
                    "profileName": "PTPN11 E76K"
                }
            ]
        },
        {
            "id": 31353,
            "profileName": "BRAF G596R PTPN11 E76K",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31356,
            "profileName": "NF1 N184fs PTPN11 E76K",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 96195,
            "transcript": "XM_006719526",
            "gDna": "chr12:g.112450406G>A",
            "cDna": "c.226G>A",
            "protein": "p.E76K",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 96193,
            "transcript": "NM_002834",
            "gDna": "chr12:g.112450406G>A",
            "cDna": "c.226G>A",
            "protein": "p.E76K",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 96194,
            "transcript": "NM_080601",
            "gDna": "chr12:g.112450406G>A",
            "cDna": "c.226G>A",
            "protein": "p.E76K",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}